Literature DB >> 2239223

Expression of epidermal growth factor receptor in laryngeal dysplasia and carcinoma.

M Miyaguchi1, J Olofsson, H B Hellquist.   

Abstract

The immunoreactivity of epidermal growth factor receptor (EGFR) was studied in laryngeal biopsy specimens from 24 patients. The study comprised 5 cases of normal laryngeal mucosa, 5 cases of dysplasia, 7 cases of well differentiated squamous cell carcinoma, and 7 cases of poorly to moderately differentiated squamous cell carcinoma. EGFR was in general not expressed in normal and dysplastic epithelia, whilst all carcinomas showed a rather strong positive immunoreactivity. There was no significant difference in staining patterns between the well and poorly to moderately differentiated carcinomas. The results suggest that EGFR constitutes a component of neoplastic, but probably not preneoplastic, laryngeal disease. The study failed to reveal any difference in staining pattern between different types of laryngeal squamous cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2239223     DOI: 10.3109/00016489009122553

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  12 in total

Review 1.  Prevention of head and neck cancer.

Authors:  Terry A Day; Angela Chi; Brad Neville; James R Hebert
Journal:  Curr Oncol Rep       Date:  2005-03       Impact factor: 5.075

Review 2.  Current understanding of the tumor microenvironment of laryngeal dysplasia and progression to invasive cancer.

Authors:  Sumita Trivedi; Clark A Rosen; Robert L Ferris
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2016-04       Impact factor: 2.064

Review 3.  Molecular pathogenesis of head and neck squamous cell carcinoma.

Authors:  David Hardisson
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-05-08       Impact factor: 2.503

4.  Prognostic significance of epidermal growth factor receptor in squamous cell carcinoma of the maxillary sinus.

Authors:  M Miyaguchi; S Sakai; J Olofsson; H Kuwabara; H Sakamoto
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

Review 5.  The nature of the head and neck cancer.

Authors:  A G Maran; J A Wilson; M N Gaze
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

6.  Activation of MAP kinase signaling through ERK5 but not ERK1 expression is associated with lymph node metastases in oral squamous cell carcinoma (OSCC).

Authors:  Carsten Sticht; Kolja Freier; Karl Knöpfle; Christa Flechtenmacher; Susanne Pungs; Christof Hofele; Meinhard Hahn; Stefan Joos; Peter Lichter
Journal:  Neoplasia       Date:  2008-05       Impact factor: 5.715

7.  Epidermal growth factor receptor protein expression and gene amplification in normal, hyperplastic, and cancerous glottic tissue: immunohistochemical and fluorescent in situ hybridization study on tissue microarrays.

Authors:  Tamara Braut; Mira Krstulja; Milodar Kujundzić; Dubravko Manestar; Ita Hadzisejdić; Nives Jonjić; Blazenka Grahovac; Darko Manestar
Journal:  Croat Med J       Date:  2009-08       Impact factor: 1.351

8.  A correlation of argyrophilic nucleolar organizer regions with prognoses in patients with maxillary sinus squamous cell carcinoma.

Authors:  M Miyaguchi; T Kawahara; S Sakai; H Kuwabara; H Sakamoto
Journal:  Eur Arch Otorhinolaryngol       Date:  1994       Impact factor: 2.503

9.  Prognostic significance of methyl-p-hydroxy-phenyllactate-esterase activity in laryngeal squamous cell carcinoma.

Authors:  M Maurizi; G Ferrandina; G Almadori; G Scambia; G Cadoni; G D'Agostino; F G Serra; M Piantelli; S Mancuso; F O Ranelletti
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

10.  Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma.

Authors:  M Maurizi; G Almadori; G Ferrandina; M Distefano; M E Romanini; G Cadoni; P Benedetti-Panici; G Paludetti; G Scambia; S Mancuso
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.